ABSTRACT
Vitamin D (VD) deficiency is frequently reported in heart transplant (HT) recipients and routinely supplemented. However, the efficacy of VD supplementation on bone mineral density (BMD) and its association with all-cause mortality is underinvestigated. The VD levels and BMD were studied for two years, and the association of VD and BMD with all-cause mortality risk was investigated. Ninety-six HT patients (38.18 ± 12.10 years old; 74% men) were followed up during VD, Ca, and Mg supplementation. Anthropometric measurements, BMD by Dual-energy X-ray absorptiometry (DEXA) scan, VD concentrations, and related biochemical parameters were analyzed before, 1 year, and 2 years after HT. Despite significant improvement of VD3 and 25-hydroxy VD (25OHVD) levels especially in the men, BMD parameters were insignificantly changed. After 2 years, the all-cause mortality rate was 15.6%. High pretransplant levels of 25OHVD failed to improve the survival probability. Cox's regression showed a 32.7% increased hazard ratio for each unit increase in body mass index (95% CI: 1.015-1.733, p = 0.038), in the VD-deficient group rather than in the VD-sufficient one. In conclusion, VD supplementation improves the biochemical status, especially in VD-deficient HT. However, its impact on the BMD and mortality was not as usually expected. Further investigation of the disturbed VD metabolism in HT is warranted.
ABSTRACT
Candesartan cilexetil (CC) is an antihypertensive drug. It has low solubility and faces hepatic first-pass metabolism after oral ingestion. We formulated bioadhesive buccal films and studied the respective drug pharmacokinetics. Different bioadhesive films were prepared (40, 80, 120, 160, 200, and 240 mg CC per film) by using the solvent casting method. The drug concentrations used affect the drug entrapment mechanism, which was reflected in the film physicochemical properties like thickness, weight, drug content, bioadhesion, and drug release. Low drug concentration (F2, 40 mg per film) led to minute drug crystal dispersion while increasing the drug concentration (F7, 240 mg per film) showed drug crystal encapsulation, which affects the drug release. The drug pharmacokinetic from the prepared films was studied compared to the oral form by serial blood sampling via an inserted catheter in the carotid of rats. High-Performance Liquid Chromatography assay was used to measure the plasma concentration of CC in different forms. Compared to other films, the F2 showed the highest maximal concentration (Cmax) and the lowest elimination half-life (t1/2). Bioadhesion buccal film of CC has better bioavailability, especially at low concentrations. The ease, robustness, and ruggedness of the preparation suggests the same procedure for drugs like CC.
ABSTRACT
Despite various mechanical and chemical surface-pretreatment methods, long-term bonding of resin composite to dental zirconia (ZrO2 ) remains a major concern. In this study, graphene oxide (GO) sheets were infused into two commercially available primers and the enclosed mould shear bond strength (EM-SBS) of resin composite to ZrO2 was evaluated. Twelve fully sintered ZrO2 blanks were pretreated and randomly allocated to four groups according to the primers used: RelyX (RX); GO blended RelyX (RXGO); Monobond-S (MB); and GO blended Monobond-S (MBGO). The resin composite stubs were bonded onto the pretreated ZrO2 surfaces and analysed at baseline and after storage in distilled water for 2 and 4 months. The experimental primers blended with GO sheets influenced the surface morphology, visualized as increased surface roughness, and slightly increased the water contact angle measurements. Moreover, the infusion of primers with GO increased the mass fraction (wt%) of carbon and oxygen. The highest EM-SBS values were found for RXGO, with mean (SD) EM-SBS values of 26.4 (3.7) MPa and 21.5 (5.1) MPa after 2 and 4 months of storage, respectively. Infusion of silane primers with nanometre- to micrometre-size GO sheets enhanced the SBS between resin composite and ZrO2 .
